A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

Clinical trial NCT02338349 · COMPLETED

Trial details

NCT number: NCT02338349
Sponsor: Stemline Therapeutics, Inc.
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced ER+, HER2-Negative Breast Cancer

Start date: 2015-01-01
Primary completion: 2019-09-01
Enrollment: 57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.